Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 801 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement... February 27, 2024 What People With Cancer and Survivors Should Know About Vaping: An... September 26, 2023 Patient Guide in Testicular Cancer Now Available Also in Italian November 25, 2025 Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of... March 11, 2025 Load more HOT NEWS ΜΥΘΟΙ ΚΑΙ ΑΛΗΘΕΙΕΣ When You Have Cancer and You’re a Parent: “Your Stories” Podcast How My Stage 4 Esophageal Cancer Diagnosis Led Me to a... Two Women With Terminal Breast Cancer Started A Podcast That’s Unflinchingly...
